These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 6508315)

  • 1. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
    Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
    Takahashi K; Yokoyama M; Takahashi H; Wakui A
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
    Meguro S; Nagata T; Yokoyama K; Chinen T; Kobayashi T; Yamazaki H; Kuraishi Y; Ichiba ; Abe M; Isogai Y
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa].
    Shimizu E; Saijo N; Shinkai T; Eguchi K; Tominaga K; Nomori H; Sasaki Y; Garcia-Herreros P; Hoshi A
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1290-5. PubMed ID: 6732255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H; Hoshi A
    Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].
    Taguchi T; Wakui A; Nabeya K; Kurihara M; Isono K; Kakegawa T; Ota K
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):483-8. PubMed ID: 1558398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
    Meguro S; Nagata T; Yokoyama K; Chinen T; Yamazaki H; Kobayashi T; Isogai Y; Ogawa M
    Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.
    Hartmann JT; Kanz L; Bokemeyer C
    Anticancer Res; 2000; 20(2B):1177-82. PubMed ID: 10810418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in gastrointestinal cancer].
    Takenaka K; Tamada R; Hiramoto Y; Inokuchi K; Saku M; Oka N; Kano T; Noda S; Nagasaki S; Toda T
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2155-60. PubMed ID: 4062315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
    Fujii M; Murakami N; Matsuka Y; Ejiri T; Asano K
    Gan No Rinsho; 1983 Feb; 29(2):A-8, 129-32. PubMed ID: 6308301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A phase I trial of 4'-epiadriamycin].
    Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A phase II study of ranomustine (MCNU) tablets in patients with gastrointestinal cancer--by cooperative study group].
    Taguchi T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2420-6. PubMed ID: 6497400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase II study of SM-5887 for advanced gastric cancer].
    Tsushima K; Sakata Y; Munakata A; Sato T; Chiba Y; Nara H; Kawazu S; Matsukawa M; Ohmi T; Aizawa T
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1151-4. PubMed ID: 1647150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II study of VP-16 (capsule) in solid tumors. A cooperative study].
    Honma T; Ogawa M; Yoshida S; Meguro S; Hirano M; Hoshino A; Shirakawa S; Nakamura T; Fukuoka M; Toki H
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):309-13. PubMed ID: 2982332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
    de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
    Nishiyama M; Kim R; Saeki T; Takagami S; Kirihara Y; Jinushi K; Toge T; Niimoto M; Hattori T
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3133-7. PubMed ID: 3142368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.